Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics Seeking Federal Support For NCP Depression Pivotal Trial

This article was originally published in The Gray Sheet

Executive Summary

Cyberonics' NCP NeuroCybernetic Prosthesis system eliminated symptoms of major depressive episodes in at least 25% of patients having completed the acute phase of a pilot study evaluating the vagus nerve stimulation therapy for major chronic depression.

You may also be interested in...



CYBERONICS' NCP DEVICE FOR EPILEPSY INITIAL COMMERCIAL IMPLANT SET FOR JULY 24; FDA APPROVAL COMES LESS THAN THREE WEEKS AFTER PANEL REVIEW

The first commercial implant of Cyberonics' NeuroCybernetic Prosthesis (NCP) system is slated for July 24 following FDA's July 16 approval of a premarket approval application for the implantable vagus nerve stimulator for treating epilepsy.

Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic

Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.

Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel